StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a report issued on Sunday. The firm set a “sell” rating on the stock. Several other analysts have also recently ...

OncoCyte (OCX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices ...

Bio-Rad Laboratories, Inc.’s BIO Clinical Diagnostics business is back to its usual growth trajectory post-pandemic while maintaining a strong market position worldwide for key platforms. The ...

Event: 24th Annual Needham Virtual Healthcare Conference Dates: April 7-10, 2025 Oncocyte Fireside Chat: April 7, 2025, 3:45 PM (ET) Location: Virtual For more information about Oncocyte and its ...

(NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, is working together with ...

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report published on Monday morning. The firm issued a sell rating on the stock. OCX has been the topic of a ...

EDT OncoCyte (OCX) files to sell 10.61M shares of common stock for holdersDon't Miss Our End of Quarter Offers: Discover the latest ...

Lake Street 分析师认为，OncoCyte 目前的市场估值并未反映公司的潜力，表明当前股价为长期投资者提供了一个有吸引力的入场点。该公司启动覆盖并给予"买入"评级和5美元的目标价是基于这些因素，表明对 OncoCyte 未来表现的信心。随着公司下一次财报将于4月4日发布，投资者可以通过 InvestingPro ...

Astute Analytica research report titled “Global Breast Cancer Screening Market Report 2024″ presents an exhaustive analysis and strategic insights into the evolving landscape of the Breast Cancer ...

Stephens & Co.：重申OncoCyte(OCX.US)评级，由持股观望调整至持股观望评级, 目标价由4.00美元调整至4.00美元。 OncoCyte（OCX.US）公司简介：OncoCyte Corp 专注于 ...

OncoCyte Corp (NASDAQ:OCX) launched Graft Assure, a kidney transplant test, with leading transplant centers, enhancing their IVD product development. The company achieved a breakthrough ...

OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call Transcript March 24, 2025 OncoCyte Corporation misses on earnings expectations. Reported EPS is $-1.92791 EPS, expectations were $-0.4.